Standard BioTools Inc. Deferred Income Tax Expense (Benefit)
Standard BioTools Inc. (LAB) reported Deferred Income Tax Expense (Benefit) of -$38.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-16
- Standard BioTools Inc. deferred income tax expense (benefit) for fiscal 2025 was -$38.77M, a 18919.42% decline from fiscal 2024.
- Standard BioTools Inc. deferred income tax expense (benefit) for fiscal 2024 was $206.00K.
- Standard BioTools Inc. deferred income tax expense (benefit) for fiscal 2023 was -$118.00K.
- Standard BioTools Inc. deferred income tax expense (benefit) for fiscal 2022 was -$3.32M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$38.77M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $206.00K 10-K · filed 2026-03-16 | $237.00K 10-K · filed 2025-03-11 |
| 2023-12-31 | -$118.00K 10-K · filed 2026-03-16 | |
| 2022-12-31 | -$3.32M 10-K · filed 2025-03-11 | |
| 2021-12-31 | -$4.32M 10-K · filed 2023-03-14 | |
| 2020-12-31 | -$3.43M 10-K · filed 2022-03-08 | |
| 2019-12-31 | -$2.51M 10-K · filed 2022-03-08 | |
| 2018-12-31 | -$2.48M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$3.78M 10-K · filed 2020-02-27 | |
| 2016-12-31 | -$3.92M 10-K · filed 2019-03-18 | |
| 2015-12-31 | -$2.84M 10-K · filed 2018-03-08 | |
| 2014-12-31 | -$5.15M 10-K · filed 2017-03-03 | |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 | |
| 2012-12-31 | $0.00 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |